Anixa Biosciences: FDA Asks Addl Information For CAR-T Therapy; Stock Plunges

Anixa Biosciences Inc. (ANIX) said Monday that the U.S. Food and Drug Administration has requested additional information regarding its Chimeric Antigen Receptor-T cell therapy or CAR-T being developed in partnership with Moffitt Cancer Center or MCC.

In Monday regular trading, ANIX was trading at $4.01, down $0.69 or 14.68%.

Anixa noted that the study under the Investigational New Drug or IND application has been placed on clinical hold pending submission of additional information requested by the FDA.

Anixa expects, within the next 30 days, the FDA will provide a letter to MCC with detailed and specific information requested. MCC will assemble and submit information addressing the request as soon as possible there after. Successive to the submission, the FDA will continue its review of the IND.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration approved Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa (dabigatran etexilate) oral blood thinning medication for children. Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth. The only other approved blood thinning medication for children is given by injection. Amazon.com Inc.'s two-day Prime Day event is happening now with more than 2 million deals on offer. The e-commerce giant's biggest shopping extravaganza of the year started June 21 at 3 a.m. EDT and runs for 48 hours, through June 22. Prime Day 2021 will feature the largest number of deals ever offered in the seven year history of the Prime Day Celebrations. New deals are being launched throughout The European Commission announced Tuesday that it has opened a formal antitrust investigation to assess whether Google has violated EU competition rules by favoring its own online display advertising technology services in the so called "ad tech" supply chain, to the detriment of competing providers...
Follow RTT